Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure

American Journal of Medicine

Volumn 129, Issue 10, 2016, Pages 1067-1073

  Sanam, Kumar ^a   Bhatia, Vikas ^b   Bajaj, Navkaranbir S ^b   Gaba, Saurabh ^b   Morgan, Charity J ^b   Fonarow, Gregg C ^c   Butler, Javed ^d   Deedwania, Prakash ^e   Prabhu, Sumanth D ^b,f   Wu, Wen Chih ^g   White, Michel ^h   Love, Thomas E ⁱ   Aronow, Wilbert S ^j   Fletcher, Ross D ^k   Allman, Richard M ^l   Ahmed, Ali ^k  

^a St John Providence Health System   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BIRMINGHAM VA MEDICAL CENTER   (United States)

^g PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j NEW YORK MEDICAL COLLEGE   (United States)

^k VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l DEPARTMENT OF VETERANS AFFAIRS   (United States)

more..

Author keywords

ACEI or ARB; Heart failure; Hospital readmission

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ALABAMA; ARTICLE; DRUG USE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; CAUSE OF DEATH; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HOSPITALIZATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROTECTION; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALABAMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAUSE OF DEATH; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MEDICARE; MIDDLE AGED; MORTALITY; PATIENT READMISSION; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RENIN-ANGIOTENSIN SYSTEM; STROKE VOLUME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84990058428     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.05.008     Document Type: Article

References (23)

1. 1 Jencks, S.F., Williams, M.V., Coleman, E.A., Rehospitalizations among patients in the Medicare Fee-for-Service program. N Engl J Med 360 (2009), 1418–1428.
2. 2 Boccuti C, Casillas G. Aiming for fewer hospital u-turns: the medicare hospital readmission reduction program. Kaiser family foundation. Available at: http://kff.org/medicare/issue-brief/aiming-for-fewer-hospital-u-turns-the-medicare-hospital-readmission-reduction-program/. Accessed April 18, 2016.
3. 3 Davis K, Guterman S, Bandeali F. The affordable care act and medicare: how the law is changing the program and the challenges that remain. The commonwealth fund. Available at: http://www.commonwealthfund.org/∼/media/files/publications/fund-report/2015/jun/1821_davis_aca_and_medicare_v2.Pdf. Accessed April 18, 2016.
4. 4 Feltner, C., Jones, C.D., Cene, C.W., et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 160 (2014), 774–784.
5. 5 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
6. 6 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302.
7. 7 Ahmed, A., Bourge, R.C., Fonarow, G.C., et al. Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med 127 (2014), 61–70.
8. 8 Bourge, R.C., Fleg, J.L., Fonarow, G.C., et al. Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med 126 (2013), 701–708.
9. 9 The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997), 525–533.
10. 10 Feller, M.A., Mujib, M., Zhang, Y., et al. Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: findings from the Alabama Heart Failure Project. Int J Cardiol 162 (2012), 39–44.
11. 11 Bhatia, V., Bajaj, N.S., Sanam, K., et al. Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure. Am J Med 128 (2015), 715–721.
12. 12 Danaei, G., Tavakkoli, M., Hernan, M.A., Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 175:4 (2012), 250–262.
13. 13 Ahmed, A., Fonarow, G.C., Zhang, Y., et al. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med 125 (2012), 399–410.
14. 14 Edner, M., Benson, L., Dahlstrom, U., Lund, L.H., Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J 36:34 (2015), 2318–2326.
15. 15 Rosenbaum, P.R., Rubin, D.B., The central role of propensity score in observational studies for causal effects. Biometrika 70 (1983), 41–55.
16. 16 Rubin, D.B., The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 26 (2007), 20–36.
17. 17 Ahmed, A., Husain, A., Love, T.E., et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 27 (2006), 1431–1439.
18. 18 Ahmed, M.I., White, M., Ekundayo, O.J., et al. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur Heart J 30 (2009), 2029–2037.
19. 19 Wahle, C., Adamopoulos, C., Ekundayo, O.J., Mujib, M., Aronow, W.S., Ahmed, A., A propensity-matched study of outcomes of chronic heart failure in younger and older adults. Arch Gerontol Geriatr 49 (2009), 165–171.
20. 20 Granger, C.B., McMurray, J.J., Yusuf, S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003), 772–776.
21. 21 Fonarow, G.C., Abraham, W.T., Albert, N.M., et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297 (2007), 61–70.
22. 22 Hernandez, A.F., Hammill, B.G., O'Connor, C.M., Schulman, K.A., Curtis, L.H., Fonarow, G.C., Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 53 (2009), 184–192.
23. 23 Butler, J., Arbogast, P.G., Daugherty, J., Jain, M.K., Ray, W.A., Griffin, M.R., Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol 43 (2004), 2036–2043.